Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration

Cell Communication and Signaling - Tập 11 Số 1 - 2013
A. Koop1, Nadia Sellami2, Sabine Adam‐Klages1, Marcus Lettau1, Dieter Kabelitz1, Ottmar Janßen1, Hans-Jürgen Heidebrecht2
1Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Bldg 17, Kiel, 24105, Germany
2Institute for Pathology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Bldg 14, Kiel, 24105, Germany

Tóm tắt

Abstract Background Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease score in Hodgkin’s lymphoma and poor prognosis in multiple myeloma. As for many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown. Methods CT45 expression was down-regulated in CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma (HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive capacity of tumor cells. Results Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However, we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation. Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging. Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation and cell motility. Conclusions Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.

Từ khóa


Tài liệu tham khảo

Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004, 4: 1-

Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, JongeneeL CV, Simpson AJG, Old LJ, Hide W: Genome-wide analysis of cancer/testis gene expression. PNAS. 2008, 105: 20422-27. 10.1073/pnas.0810777105.

Almeida LG, Sakabe NJ, DeOliveira AR, Silva MCC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJG, Old LJ, Camargo AA, Vasconcelos AT: CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009, 37: D816-D819. 10.1093/nar/gkn673.

Boon T, Old LJ: Cancer Tumor antigens. Curr Opin Immunol. 1997, 9: 681-683. 10.1016/S0952-7915(97)80049-0.

Fratta E, Coral S, Covre A, Parisi G, Collizzi F, Danielli R, Nicolay HJM, Sigalotti L, Maio M: The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol Oncol. 2011, 5: 164-182. 10.1016/j.molonc.2011.02.001.

Simpson AJG, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005, 5: 621-25.

Old LJ: Cancer vaccines: an overview. Cancer Immun. 2008, 8 (Suppl.1): 1-5.

Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulus N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbersthon A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffmann EW, Old LJ, Cebon JS: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. PNAS. 2004, 29: 10697-10702.

Brichard VG, Lejeune D: GSK’s antigen-specific cancer immunotherapy programme: Pilot results leading to phase III clinical development. Vaccine. 2007, 25S: B61-B71.

Chen YT, Scanlan MJ, Vendetti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausber AL, Jongeneel CV, Old LJ, Simpson JG: Identification of cancer/testis–antigen genes by massive parallel signature sequencing. PNAS. 2005, 102: 7940-7945. 10.1073/pnas.0502583102.

Rudolph P, Kellner U, Schmidt D, Kirchner V, Talerman A, Harms D, Parwaresch R: Ki-A10, a germ cell nuclear antigen retained in a subset of germ cell-derived tumors. Am J Path. 1999, 154: 795-803. 10.1016/S0002-9440(10)65326-6.

Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S, Tiemann M, Dörffel W, Parwaresch R: Characterization and expression of CT45 in Hodgkin’s lymphoma. Clin Cancer Res. 2006, 12: 4804-4811. 10.1158/1078-0432.CCR-06-0186.

Andrade VCC, Vettore AL, Silva MRR, Felix RS, Almeida MSS, de Carvalho F, Zogo MA, Caballero ML, Simpson AJ, Colleoni GWB: Frequency and prognostic relevance of cancer/testis 45 expression in multiple myeloma. Exp Hematol. 2009, 37: 446-449. 10.1016/j.exphem.2008.12.003.

Chen Y-T, Hu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Song C-J, Jin B-Q, Simpson AJ, Old LJ: Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer. 2009, 124: 2893-2898. 10.1002/ijc.24296.

Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A, Gnjatic S, Preundschuh M, Knowles DM, Old LJ: Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. PNAS. 2010, 107: 3093-3098. 10.1073/pnas.0915050107.

De Smet C, Lurquin C, Lethe B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promotor. Mol Cell Biol. 1999, 19: 7327-7335.

Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, Kim H, Lee YS Kang GH, Jeoung DI: Promotor hypomethylation of a novel cancer/testis antigen gene is correlated with its aberrant expression in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun. 2003, 307: 52-63. 10.1016/S0006-291X(03)01121-5.

Heidebrecht HJ, Kruse ML, Janßen O, Parwaresch R: Cancer/testis antigen CT45 is expressed in a nuclear speckle-like pattern in human tumor cell lines [abstract]. CCS. 2009, 7 (Suppl I): A31-

Claviez A, Mauz-Körholz C, Heidebrecht HJ, Schellong G, Körholz D, Dörffel W, Parwaresch R, Tiemann M: Cancer/Testis antigen is frequently expressed in Hodgkin’s lymphoma and associated with nodular sclerosis subtype and advanced disease [abstract]. Blood. 2006, 108: 4591-

Claviez A, Heidebrecht H-J, Dörffel R, Parwaresch R, Tiemann M: CT45 Expession in pediatric Hodgkin’s lymphoma is associated with nodular sclerosis subtype, presence of B symptoms and advanced disease stages [abstract]. Haematologica. 2007, 92 (Suppl): s5-

Yang B, O’Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal Y, Longly BJ: Select cancer testes antigens of the MAGE-A, -B and –C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol. 2007, 127: 267-275. 10.1038/sj.jid.5700548.

Por E, Byun H-J, Lee E-J, Lim J-H, Jung A-Y, Park I, Kim Y-M, Jeoung D-I, Lee H: The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F dependent manner. J Biol Chem. 2010, 285: 14475-14485. 10.1074/jbc.M109.084400.

Jungbluth AA, Ely S, DiLiberto M, Niesvitzky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005, 106: 167-174. 10.1182/blood-2004-12-4931.

Cronwright G, Le Blanc K, Götherstöm C, Darcy P, Ehnman M, Brodin B: Cancer/testis antigen expression in human mesenchymal stem cells: Downregulation of SSX impairs cell migration and and matrix metalloproteinase 2 expression. Cancer Res. 2005, 65: 2207-2215. 10.1158/0008-5472.CAN-04-1882.

Mourelatos Z, Abel L, Yong J, Kataoka N, Dreyfuss G: SMN interacts wuth a noval family of hnRNP and spliceosomal proteins. EMBO J. 2001, 20: 5443-5452. 10.1093/emboj/20.19.5443.

Xing L, Yao X, Williams KR, Bassel GJ: Negative regulation of RhoA translation and signalling by hnRNP-Q1 affects cellular morphogenesis. Mol Cell Biol. 2012, 23: 1500-1509. 10.1091/mbc.E11-10-0867.

Chen HH, Yu H, Chiang WC, Lin YD, Shia BC, Tarn WY: hnRNP Q regulates Cdc42-mediated neuronal morphogenesis. Mol Cell Biol. 2012, 32: 2224-2238. 10.1128/MCB.06550-11.

Mintz PJ, Patterson SD, Neuwald AF, Spahr CS, Spector DL: Purification and biochemical characterization of interchromatin granule clusters. EMBO J. 1999, 18: 4308-4320. 10.1093/emboj/18.15.4308.

Pollmann M, Parwaresch R, Adam-Klages S, Kruse ML, Buck F, Heidebrecht HJ: Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res. 2006, 312: 3241-3251. 10.1016/j.yexcr.2006.06.035.

Atanackovic D, Hildebrand Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kröger N: Cancer-testis antigens MAGE-C1/CT/7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010, 95: 785-793. 10.3324/haematol.2009.014464.

Kim Y, Jeoung D: Role of CAGE, a novel cancer/testis antigen, in various cellular processes, including tumorgenesis, cytolytic T lymphocyte induction, and cell motility. J Microbiol Biotechnol. 2008, 18: 600-610.

Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated molecular process. Cell. 1996, 84: 359-369. 10.1016/S0092-8674(00)81280-5.

Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P: L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012, 6: 374-84. 10.4161/cam.20832.

Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C, Clark SJ: Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2013, 23: 9-22. 10.1016/j.ccr.2012.11.006.

Heidebrecht HJ, Adam Klages S, Szczepanowski M, Pollmann M, Buck F, Endl E, Kruse ML, Rudolph P, Parwaresch R: repp86: A human protein associated in the progression of mitosis. Mol Cancer Res. 2003, 1: 271-279.

Thông tin
Thông tin xuất bản

Cell Communication and Signaling

Tập 11 Số 1

Thông tin tác giả